ClinicalTrials.gg
Sign In
CompletedNCT04518033MeDiCUpdated Jan 20, 2022

Measuring Droplets in Children

An interventional study of Various commercially available face coverings in Droplet Spread, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 3 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-20.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
3 Years to 17 Years
Sex
All
01

Study summary

This study will measure the size and quantity of respiratory particle production in children under a variety of conditions, including face coverings/masks and various common activities.

02

Conditions studied

  • Droplet Spread
03

In context

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,582 studies on the registry; 451 are open to participants now.

Of its 221 completed or terminated interventional studies of FDA-regulated products, 168 (76%) have results posted.

Browse Massachusetts General Hospital studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Age 3 to 17 years

Exclusion criteria

Exclusion Criteria:

  • Chronic neuromuscular conditions that affect respiration
  • Tracheostomy tube
  • Unable to wear a face mask
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Face covering use

    Participants will be provided various commercially available face coverings

    Device: Various commercially available face coverings

Interventions

  • DeviceVarious commercially available face coverings

    Various commercially available face coverings

06

What researchers measure

Primary outcomes

  1. Respiratory particle production

    Time frame: 2 hours

07

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Apr 2021, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2020
First posted
Aug 19, 2020
StartActual
Apr 3, 2021
Primary completionActual
Apr 23, 2021
CompletionActual
Apr 23, 2021
Last update
Jan 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04518033
Lead sponsor
Massachusetts General Hospital
Collaborators
Harvard School of Public Health (HSPH)
Responsible party
Peter Moschovis (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Aug 19, 2020
Start date
Apr 3, 2021
Primary completion
Apr 23, 2021
Completion
Apr 23, 2021
Last update
Jan 20, 2022

Study contacts

Peter P Moschovis, MD, MPH
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Massachusetts General Hospital →

Start the discussion